Swiss Deal Ledger Pharma & life sciences

Roche → 89bio

Roche acquired 89bio, a US biotech developing pegozafermin for liver disease, for cash plus a contingent value right tied to future milestones.

Announced September 2025OutboundCompleted

  • Up to USD 3.5bn incl. CVRValue as disclosed
  • CompletedCompleted 30 October 2025
  • OutboundSwiss buyer, foreign target
  • Sep 2025Announced
David BaburiHead of Research, Valstron
Share

The record

One line of the Swiss Deal Ledger
BuyerRoche
Target89bio
SectorPharma & life sciences
DirectionOutbound (swiss buyer, foreign target)
ValueUp to USD 3.5bn incl. CVR
AnnouncedSeptember 2025
StatusCompleted
DetailCompleted 30 October 2025
SourcePharmaceutical Technology

On the Ledger

One of 7 pharma and life sciences transactions on the Ledger.

Open the full Ledger

Spotted a change on this deal? research@valstron.ch

The Valstron Brief

New Deal Snapshots, delivered.

Every new Snapshot and selected perspectives, on the day they are published.